<DOC>
	<DOCNO>NCT02116803</DOCNO>
	<brief_summary>The study allow continue safety follow-up patient single agent dovitinib dovitinib combination fulvestrant treatment Novartis-sponsored study meet primary endpoint benefiting treatment judge investigator .</brief_summary>
	<brief_title>An Open Label Multi-center Extension Study Evaluate Long-term Safety/ Tolerability Dovitinib Patients With Solid Tumors Who Continue Receive Treatment With Dovitinib ( TKI258 ) Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled Requirements Primary Objective</brief_title>
	<detailed_description />
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>patient currently enrol Novartis sponsor study , meet endpoint receive single agent oral dovitinib dovitinib fulvestrant coadministration patient currently benefit treatment single agent oral dovitinib dovitinib fulvestrant coadministration determine guideline parent protocol accord investigator 's clinical judgment . patient demonstated compliance patient give write informed consent . patient permanently discontinue oral dovitinib study treatment , either alone combination fulvestrant , parent study patient pregnant nursing time entry woman childbearing potential male patient sexual partner childbearing potential unwilling use highly effective method contraception dose specify duration stop study treatment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>solid tumor ,</keyword>
	<keyword>TKI258</keyword>
</DOC>